ArticleCureus2026
Isocitrate Dehydrogenase (IDH)-Wildtype Glioblastoma With an Unusual EWSR1::RAD51B Gene Fusion: A Case Report and Review of the Literature.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Glioblastoma (GBM) is the most common primary malignant neoplasm of the central nervous system in adults. GBM is defined as an isocitrate dehydrogenase (IDH)-wildtype diffuse astrocytic glioma with characteristic histologic and/or molecular features. The expanding use of integrated histologic, molecular, and epigenetic diagnostics has revealed increasing biological heterogeneity within this category. We report a case of a 73-year-old man with GBM, IDH-wildtype, harboring a novel EWSR1::RAD51B gene fusion identified by next-generation sequencing (NGS). Magnetic resonance imaging revealed a heterogeneous, predominantly peripherally enhancing mass involving the left temporal, parietal, and occipital lobes. Histologic examination demonstrated a diffusely infiltrative high-grade glioma with marked nuclear pleomorphism, brisk mitotic activity, microvascular proliferation, and geographic and pseudopalisading necrosis. Immunohistochemistry was supportive of GBM. Molecular studies revealed MGMT promoter methylation and a truncating PTEN mutation (p.Q214*, c.640C>T). In addition, a previously unreported EWSR1::RAD51B gene fusion was identified by NGS. DNA methylation profiling also classified the tumor as GBM, IDH-wildtype, with high confidence. To our knowledge, this is the first reported case of GBM harboring an EWSR1::RAD51B gene fusion. Although the biological significance of this alteration remains unclear, its identification expands the molecular spectrum of GBM and underscores the value of comprehensive genomic and epigenomic profiling in the diagnostic evaluation of diffuse gliomas, particularly when unexpected or atypical molecular findings are encountered.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.